
Zeto
A medical technology startup that's democratizing EEG (Electroencephalography) for healthcare.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
* | $31.0m | Series B | |
Total Funding | 000k |
Related Content
Zeto Inc., a medical technology company founded in 2014, is focused on advancing brain monitoring through its electroencephalography (EEG) solutions. The company was established by Aswin Gunasekar, a former electrical engineer and management consultant, whose personal experience with a cousin's epilepsy inspired him to improve the cumbersome EEG process. Gunasekar's background in microprocessor design at AMD and management consulting at PwC provided a strong foundation for developing and marketing sophisticated medical technology.
Zeto operates in the health technology sector, specifically targeting the brain monitoring market. Its clients include hospitals, physician offices, neuroscience research labs, and clinical trial organizations. The company's business model combines the sale of its proprietary hardware with a subscription-based software-as-a-service (SaaS) cloud platform. This platform provides nationwide monitoring and remote interpretation services by neurologists, supplemented by AI-driven notifications for conditions like seizures.
The company's core products are wireless, dry-electrode EEG headsets, notably the zEEG, WR19, and the more recent Zeto ONE. These headsets are designed for quick setup—in under five minutes—without the need for skin preparation, gels, or pastes, which is a significant departure from traditional EEG procedures. Key features include soft-tip electrodes positioned according to the international 10-20 system, a lightweight design, and a rechargeable battery. The headsets stream data wirelessly to the HIPAA-compliant Zeto Cloud, allowing for live remote viewing, data management, and analysis. The platform also includes AI-enabled seizure notifications and workflow management tools.
Significant milestones for Zeto include receiving its first FDA 510(k) clearance in 2018 for its zEEG headset, another for its WR19 headset, and a further clearance in 2024 for the Zeto ONE system for use in various settings, including critical care and at home. The company has secured substantial funding, including a Series A round of $7.3 million in 2020 and a Series B round of $31 million in early 2025, to accelerate commercialization and research. In August 2024, Zeto was ranked No. 1311 on the Inc. 5000 list of fastest-growing private companies in America.
Keywords: EEG, brain monitoring, electroencephalography, medical technology, healthtech, neurodiagnostics, wireless EEG, dry electrode headset, cloud EEG platform, seizure detection, epilepsy monitoring, neurological disorders, remote neurological interpretation, medical devices, neurotechnology, clinical EEG, AI in healthcare, SaaS in healthcare, point-of-care diagnostics, digital health